Multiple myeloma

Sarah A. Holstein; Hong Liu; Philip L. McCarthy

doi:10.1016/j.hoc.2014.08.010

Multiple myeloma

Sarah A. Holstein, Hong Liu, Philip L. McCarthy

Research output: Contribution to journal › Review article › peer-review

8 Scopus citations

Abstract

Autologous stem cell transplant (ASCT) remains an integral part of the treatment strategy for many myeloma patients. The role of allogeneic stem cell transplant continues to be defined. There is increasing evidence that posttransplant maintenance therapy can significantly improve outcomes. It is predicted that with more routine use of cytogenetic and gene expression profiling in the future, we will be better able to identify those subgroups of patients who are expected to benefit most from early versus late versus no ASCT and those who will benefit from allogeneic stem cell transplant.

Original language	English (US)
Pages (from-to)	1113-1129
Number of pages	17
Journal	Hematology/Oncology Clinics of North America
Volume	28
Issue number	6
DOIs	https://doi.org/10.1016/j.hoc.2014.08.010
State	Published - Dec 1 2014
Externally published	Yes

Keywords

Immunomodulatory agents
Maintenance therapy
Proteasome inhibitors
Reduced-intensity conditioning

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.hoc.2014.08.010

Cite this

@article{0678729d0cd4463d8b434555b9e0f8a4,

title = "Multiple myeloma",

abstract = "Autologous stem cell transplant (ASCT) remains an integral part of the treatment strategy for many myeloma patients. The role of allogeneic stem cell transplant continues to be defined. There is increasing evidence that posttransplant maintenance therapy can significantly improve outcomes. It is predicted that with more routine use of cytogenetic and gene expression profiling in the future, we will be better able to identify those subgroups of patients who are expected to benefit most from early versus late versus no ASCT and those who will benefit from allogeneic stem cell transplant.",

keywords = "Immunomodulatory agents, Maintenance therapy, Proteasome inhibitors, Reduced-intensity conditioning",

author = "Holstein, {Sarah A.} and Hong Liu and McCarthy, {Philip L.}",

note = "Publisher Copyright: {\textcopyright} 2014 Elsevier Inc.",

year = "2014",

month = dec,

day = "1",

doi = "10.1016/j.hoc.2014.08.010",

language = "English (US)",

volume = "28",

pages = "1113--1129",

journal = "Hematology/Oncology Clinics of North America",

issn = "0889-8588",

publisher = "W.B. Saunders",

number = "6",

}

TY - JOUR

T1 - Multiple myeloma

AU - Holstein, Sarah A.

AU - Liu, Hong

AU - McCarthy, Philip L.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Autologous stem cell transplant (ASCT) remains an integral part of the treatment strategy for many myeloma patients. The role of allogeneic stem cell transplant continues to be defined. There is increasing evidence that posttransplant maintenance therapy can significantly improve outcomes. It is predicted that with more routine use of cytogenetic and gene expression profiling in the future, we will be better able to identify those subgroups of patients who are expected to benefit most from early versus late versus no ASCT and those who will benefit from allogeneic stem cell transplant.

AB - Autologous stem cell transplant (ASCT) remains an integral part of the treatment strategy for many myeloma patients. The role of allogeneic stem cell transplant continues to be defined. There is increasing evidence that posttransplant maintenance therapy can significantly improve outcomes. It is predicted that with more routine use of cytogenetic and gene expression profiling in the future, we will be better able to identify those subgroups of patients who are expected to benefit most from early versus late versus no ASCT and those who will benefit from allogeneic stem cell transplant.

KW - Immunomodulatory agents

KW - Maintenance therapy

KW - Proteasome inhibitors

KW - Reduced-intensity conditioning

UR - http://www.scopus.com/inward/record.url?scp=84912532689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912532689&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2014.08.010

DO - 10.1016/j.hoc.2014.08.010

M3 - Review article

C2 - 25459182

AN - SCOPUS:84912532689

SN - 0889-8588

VL - 28

SP - 1113

EP - 1129

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

IS - 6

ER -

Multiple myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this